- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02296983
A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.
Previous Ebola outbreaks have been limited to individual countries and contained by infection control activities. The current outbreak in West Africa is international, and air travel has resulted in a number of infected travellers crossing national borders. There are currently no specific treatments generally available for Ebola and the mortality is high, particularly in countries with limited intensive care facilities. There is currently no vaccine and the personal protection required by healthcare workers treating patients is cumbersome and requires full compliance to be protective.
There is now a consortium (VEBCON collaboration) of four clinical centres (in Kenya, Gabon, Switzerland and Germany), WHO and New Link Genetics (the vaccine manufacturer) under which this study will be conducted. The investigators are conducting this trial, a Phase I, open-label, dose escalation trial, designed to establish safety, tolerability and immunogenicity of two doses of VSVΔG-ZEBOV, an Ebola Virus Vaccine Candidate for the first time in sub-Saharan African populations.
The investigators plan to vaccinate 40 volunteers in Kenya. The trial will be conducted at the KEMRI-CGMR Coast site where healthcare workers (both clinical and laboratory) will be the primary target population as they are likely to be the recipients of a protective vaccine. The investigators will vaccinate a cohort of 20 volunteers at a low dose and then vaccinate a further cohort of 20 volunteers at full dose. Each volunteer will receive one dose of the vaccine. The investigators will follow them up for a period of one year looking to their safety and immunogenicity endpoints.
Study Overview
Detailed Description
This study is being conducted to assess safety and immunogenicity of an experimental ebola vaccine.
An outbreak due to the Ebola Zaire (ZEBOV) strain of unprecedented magnitude and scope and with a high mortality continues to spread across West Africa. No vaccine is currently licensed.
The specific opportunity at hand with rVSVΔG-ZEBOV-GP (BPSC1001) is to achieve long-lasting protective immunity to ZEBOV on a time scale of weeks in humans upon a single-shot vaccination, offering a discrete benefit over prime-boost vaccination protocols. The current outbreak represents a global health emergency and the need for access to therapeutic intervention and vaccines is paramount.
The vaccine investigated in this study might provide a critical tool to suppress future out-breaks of EVD in areas at risk.
This study is 1 of 4 clinical trials currently conducted as part of the WHO-led VEBCON consortium, aiming to generate harmonized data for the rVSVΔG-ZEBOV-GP (BPSC1001) vaccine candidate to allow optimized rapid decisions on dose and safety.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Coast
-
Kilifi, Coast, Kenya, 80108
- KEMRI Wellcome Trust Research Programme
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Have provided written informed consent prior to screening procedures (i.e. participants must be literate).
- Healthy adult male or non-pregnant, non-lactating female, ages 18 to 55 (inclusive) at the time of screening
- Free of clinically significant health problems, as determined by pertinent medical history, clinical examination and blood tests at screening
- Available, able, and willing to participate for all study visits and procedures
- Negative pregnancy-test for female volunteers
- Females, of non-childbearing potential who are post-menopausal (i.e. ≥ one year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)
- Females, of childbearing potential, who are willing to use effective methods of contraception for 14 days before vaccination and 30 days after vaccination.
- Males who are willing to use effective contraception following vaccination for a period of one week.
- Be willing to minimize blood and body fluid exposure of others for 5 days after vaccination
Exclusion Criteria:
• History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions.
- Known allergy to the components of the BPSC1001 vaccine product
- Unable or unwilling to stay in the study area for the period of the study and comply with study procedures.
- Ongoing participation in another clinical trial
- Receipt of licensed vaccines within 14 days of planned study immunization (30 days for live vaccines)
- Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical exam, and/or laboratory screening test
- Any serologic evidence of hepatitis B SAg or HIV infection.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes
- Have an active malignancy or history of metastatic or hematologic malignancy
- Suspected or known alcohol and/or illicit drug abuse within the past 5 years
- Moderate or severe illness and/or fever >38°C within 2 weeks prior to vaccination
- Pregnant or lactating woman or a woman who intends to become pregnant within 30 days following vaccination.
- Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period
- Administration of chronic (defined as more than 14 days) immunosuppressant's or other immune modifying drugs within 6 months of study entry
- Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose arm
The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.
|
VSV-ZEBOV
Other Names:
|
Experimental: Full dose arm
The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.
|
VSV-ZEBOV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The nature, frequency, and severity of adverse events (AEs) and/or serious adverse events (SAEs) with causal link to the study intervention
Time Frame: Days 0-30
|
To evaluate the safety and tolerability of two different doses of VSVΔG-ZEBOV vaccine
|
Days 0-30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of local and systemic reactogenicity signs and symptoms
Time Frame: Day 0-28
|
Day 0-28
|
|
Incidence of unsolicited adverse events (AEs)
Time Frame: Days 0-28
|
Days 0-28
|
|
Incidence of serious adverse events (SAEs)
Time Frame: Days 0-365
|
Days 0-365
|
|
Distribution of values of safety laboratory measures at baseline and at follow-up visits post-vaccination
Time Frame: Day 0-30
|
The distribution of values of safety laboratory measures will include the assessment of complete blood count (with differential white cell count), creatinine and alanine transaminase levels at baseline and day 7 and 30 following vaccine administration.
|
Day 0-30
|
Persistence of titres of ZEBOV-specific IgG antibodies
Time Frame: 0-180 days
|
0-180 days
|
|
Detection, magnitude and duration of VSV-ZEBOV viraemia and shedding
Time Frame: Day 1, 3 and 7
|
The detection and concentration (copies/ml) of rVSV (viral shedding) will determined in blood, urine, or saliva samples to evaluate VSV vaccine viraemia following vaccine administration.
The duration will be determined by the last timepoint with detectable viraemia.This is a composite measure.
|
Day 1, 3 and 7
|
Titres of neutralising ZEBOV-specific IgG antibodies
Time Frame: Days 7, 30, 60, 90, 180 and 365
|
Days 7, 30, 60, 90, 180 and 365
|
|
Pattern of ZEBOV specific T cell responses
Time Frame: Days 7, 30, 90, 180 and 365
|
Days 7, 30, 90, 180 and 365
|
|
Titers of ZEBOV-specific IgG antibodies
Time Frame: Days 0-28
|
Important for dose selection
|
Days 0-28
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Philip Bejon, MD, PhD, KEMRI-Wellcome Trust Collaborative Research Program
Publications and helpful links
General Publications
- Coller BG, Blue J, Das R, Dubey S, Finelli L, Gupta S, Helmond F, Grant-Klein RJ, Liu K, Simon J, Troth S, VanRheenen S, Waterbury J, Wivel A, Wolf J, Heppner DG, Kemp T, Nichols R, Monath TP. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017 Aug 16;35(35 Pt A):4465-4469. doi: 10.1016/j.vaccine.2017.05.097. Epub 2017 Jun 21.
- Medaglini D, Harandi AM, Ottenhoff TH, Siegrist CA; VSV-Ebovac Consortium. Ebola vaccine R&D: Filling the knowledge gaps. Sci Transl Med. 2015 Dec 9;7(317):317ps24. doi: 10.1126/scitranslmed.aad3106.
- Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaitre B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmuller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.
- Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaitre B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OXTREC 71-14
- SSC 2976 (Other Identifier: KEMRI Scientific Steering Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ebola Virus Disease
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Hemorrhagic Fever | Ebola Virus Vaccines | Envelope Glycoprotein, Ebola Virus | FilovirusUnited States
-
Jiangsu Province Centers for Disease Control and...Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompletedEbola DiseaseSierra Leone
-
Cerus CorporationTerminated
-
National Institute of Allergy and Infectious Diseases...CompletedEbola VirusUnited States, Congo, The Democratic Republic of the
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | EbolavirusUnited States
-
London School of Hygiene and Tropical MedicineCompletedHiv | Ebola Virus Disease | EbolaKenya, Uganda
-
Janssen Vaccines & Prevention B.V.Institut National de la Santé Et de la Recherche Médicale, France; University...CompletedEbola Viral DiseaseFrance, United Kingdom
-
MRC/UVRI and LSHTM Uganda Research UnitMinistry of Health, UgandaRecruiting
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsNot yet recruiting
Clinical Trials on VSV-ZEBOV
-
University Hospital, GenevaWellcome Trust; KEMRI-Wellcome Trust Collaborative Research Program; World Health... and other collaboratorsCompleted
-
ANRS, Emerging Infectious DiseasesNot yet recruiting
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsNot yet recruiting
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditionsUnited States
-
Amal TherapeuticsBoehringer IngelheimRecruitingPancreatic Ductal AdenocarcinomaUnited States, Switzerland
-
EpicentreMedecins Sans Frontieres, NetherlandsCompletedEbola Virus DiseaseUganda, Congo, The Democratic Republic of the
-
Universitätsklinikum Hamburg-EppendorfUniversity Hospital, Geneva; Wellcome Trust; KEMRI-Wellcome Trust Collaborative... and other collaboratorsCompletedHemorrhagic Fever, EbolaGermany
-
Universiteit AntwerpenJohnson & Johnson; University of Kinshasa; Innovative Medicines Initiative; Coalition... and other collaboratorsCompletedEbola Virus DiseaseCongo, The Democratic Republic of the
-
Centers for Disease Control and PreventionDepartment of Health and Human Services; University of Sierra Leone; Ministry... and other collaboratorsCompletedHemorrhagic Fever, EbolaSierra Leone
-
Crucell Holland BVCompleted